Nuvation Bio (NUVB) Q2 FY26 earnings call

Nuvation Bio delivered a strong second quarter, driven by robust first-line adoption of IBTROZI, which is now the market leader in new patient starts and demonstrating a shift towards a chronic disease model. The company also significantly expanded its safusidenib development program for IDH1 mutant glioma, including studies addressing post-vorasidenib progression. A successful convertible debt offering further strengthened the balance sheet, providing flexibility for continued growth and strategic opportunities.